ChiCTR2500111062
尚未开始
/
/
/
2025-10-24
/
/
acute myeloid leukemia
Maintenance Venetoclax Based Therapy Post Complete Remission In AML Fit Patients
Maintenance Venetoclax Based Therapy Post Complete Remission In AML Fit Patients
The aim of this study is to explore the efficacy of maintenance SC cytarabine + venetoclax therapy as regard disease free survival (DFS) in AML fit patients who achieved CR after highly aggressive chemotherapy as bridge for BMT or if BMT will be delayed or canceled due to any other reason.
随机平行对照
Ⅲ期
The randomization sequence will be generated by an independent statistician using a computer-based random number generator. Patients will be allocated in a 1:1 ratio to receive Venetoclax maintenance or placebo
Investigators and participants will remain blinded to the treatment allocation, ensuring that neither the enrollment process nor subsequent assessments are biased.
Sohag university
/
40
/
2025-11-01
2027-10-10
/
1-Age : 18 - 60 years . 2-Patients who are not eligible for immediate bone marrow transplantation. 3-Newly diagnosed AML patients who attained CR after 1st line. 4-Refractory / recurrant AML patients .；
请登录查看1-Patients not on CR . 2-Age : younger than 18 or older than 60 3-Patients not eligible for bone marrow transplation；
请登录查看Sohag university
/
求实药社2026-03-05
生物制品圈2026-03-05
医药观澜2026-03-05
医药观澜2026-03-05
河北省干细胞中心2026-03-05
生物制药小编2026-03-05
一度医药2026-03-05
炎明生物Pyrotech2026-03-05
药明康德2026-03-05
疑夕随笔2026-03-04
400-9696-311 转1
400-9696-311 转2
400-9696-311 转3
400-9696-311 转4
川公网安备51019002008863号
本网站未发布麻醉药品、精神药品、医疗用毒性药品、放射性药品、戒毒药品和医疗机构制剂的产品信息
“坚决打赢禁毒人民战争”专栏 法律法规 | 美、墨、欧盟管制品种
友情链接: 摩熵医药 摩熵医药企业版 摩熵化学MolAid 晓材Matmole 摩熵医学MedXYZ 载体质粒 觅健肿瘤互助 动脉网 药物百科 中国医疗人才网 医药招商网
